My Cart

Your Shopping Cart is Empty

Search

FDA Drug Import News

Import Rules Regarding Personal Medicine Orders:

Current FDA policy is not a law or a regulation, but serves as guidance for FDA personnel.

The importation of certain unapproved prescription medications for personal use may be allowed in some circumstances where these factors apply:

1). The Drug is for personal use and is a 3-month supply or less and not for resale or commercialization.

2). If no drug commercialization or drug promotion to U.S. residents by pharmacy companies involved in the distribution of the necessary drug exists.

3). If an individual seeking to import the drug affirms in writing, that it is for the patient's private use and provides the name and address of the licensed American physician responsible for treatment.

4). Provides evidence that the drug is for continuation of a treatment begun in a foreign country.

5). The intended use is for a serious condition for which effective treatment may not be available domestically.

6). If the product is not considered to represent an unreasonable health issue.

7). Overnite FedEx shipments require copy of your identification and the prescription.

Rx News

Home > BUY PSYCH DISORDER > BUY Alzheimers-Parkinsons

Dimebon (dimebon hcl) capsules 10mg x30s

Hover over image to zoom

Price: $99.00

Product ID : dimebon

Shipping Price: $25.00

0 review(s)

E-mail to a friend

Please complete this form.
All fields are required.

Your name

Your email address

Your friend's name

Your friend's email

| Add To Wish List

Purchase

The selected item is out of stock, please select a different item or combination

Description

Up until a few years ago, if you were in Russia you would be able to walk into your pharmacy and buy Dimebon over the counter. Unfortunately, when newer Russian antihistamine drugs become available Dimebon was pulled from the market. Not even Russian’s were able to buy Dimebon any more. So where can you buy Dimebon? Right now, it is not possible to buy Dimebon anywhere. However, now you can order it through our site and have it delivered to your door. Remember this product is shipped from Russia direct to you.

DIMEBON HCL., is an orally active small molecule that has been shown to inhibit brain cell death in preclinical studies of Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Research suggests that it may also have cognition-enhancing effects in healthy individuals, in the absence of neurodegenerative disease pathology.

Alzheimer's disease

Recently dimebolin has attracted renewed interest after being shown to have positive effects on persons suffering from Alzheimer’s disease. Animal studies showing potential beneficial effects on Alzheimer's disease models were shown in Russian research in 2000. Preliminary results from human trials have also been promising. In an initial six-month phase II trial, results have shown that at 12 months there was significant improvement over placebo. Dimebolin showed promising results in a Phase III-equivalent double blind trial in Russia with mild–moderate stage patients.

Apr 2009 Pfizer and Medivation initiate a phase III trial (CONCERT study) aiming for FDA approval.

Numerous phase III trials for AD were recruiting in 2009.

In July 2009 Pfizer and Medivation announced that latrepirdine will be the proposed international nonproprietary name for Dimebon for the treatment of Alzheimer's.

Pharmacology

Dimebolin appears to operate through multiple mechanisms of action, both blocking the action of neurotoxic beta-amyloid proteins and inhibiting L-type calcium channels, modulating the action of AMPA and NMDA glutamate receptors, and may exert a neuroprotective effect by blocking a novel target that involves mitochondrial pores,which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. It also blocks a number of other receptors including alpha-Adrenergic receptors and the serotonin receptor subtypes 5-HT_2C, 5-HT_5A and 5-HT₆. Dimebon lacks anticholinergic effects.

Study leaves researchers puzzled by Dimebon results

July 16, 2009 — 11:32am ET | By John Carroll

Researchers say that Medivation's experimental Alzheimer's therapy Dimebon appears to actually increase levels of the toxic protein amyloid beta while still delaying progression of the memory-wasting disease. And they don't quite know what to make of that conclusion.

"It was startling to observe that a compound with an apparently beneficial clinical effect on cognition caused acute elevation of amyloid beta levels in 3 out of 3 systems, in 2 labs," Dr. Samuel Gandy, a researcher at Mount Sinai School of Medicine in New York, tells Newsweek.

Gandy presented the data from a mouse study at an Alzheimer's meeting in Vienna. For years now researchers have concentrated on eradicating the toxic protein that builds up in the brains of Alzheimer's patients, theorizing that if you get rid of the protein you can treat the disease. But no one had figured out exactly how to target Alzheimer's. Gandy pronounced himself somewhat mystified by the results.

"We think we want amyloid levels to go down," Gandy told Reuters in a telephone interview. "Here is this compound that is looking very promising clinically that is making amyloid levels go up."

Dimebon is widely viewed as one of the most promising Alzheimer's therapies now in clinical development.

- check out the report from Reuters
- check out the story from Newsweek

Relaed Articles:
Medivation shares soar on $725M Pfizer deal
Dimebon shows positive data in Alzheimer's study
Medivation touts Phase II data on Huntington's therapy